ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OFK Orion Corporation

44.84
0.00 (0.00%)
07:54:49 - Realtime Data
Share Name Share Symbol Market Type
Orion Corporation TG:OFK Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 44.84 44.99 45.07 0.00 07:54:49

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14/10/2024 9:00am

UK Regulatory


Orion (TG:OFK)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more Orion Charts.
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

ORION CORPORATION
INVESTOR NEWS
14 OCTOBER 2024 at 11.00 EEST

        
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

Orion’s collaboration partner Bayer today announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The submission is based on positive results from the pivotal Phase III ARANOTE trial which showed that darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with mHSPC.

The compound is already approved in mHSPC, under the brand name Nubeqa™, in combination with ADT and docetaxel in over 80 markets around the world. The compound is also approved in combination with ADT for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease in more than 85 countries around the world. Darolutamide is developed jointly by Orion and Bayer.

                                                
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation

tel. +358 10 426 2721 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.


1 Year Orion Chart

1 Year Orion Chart

1 Month Orion Chart

1 Month Orion Chart

Your Recent History

Delayed Upgrade Clock